Remimazolam
- Generic Name
- Remimazolam
- Brand Names
- Byfavo
- Drug Type
- Small Molecule
- Chemical Formula
- C21H19BrN4O2
- CAS Number
- 308242-62-8
- Unique Ingredient Identifier
- 7V4A8U16MB
- Background
Remimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation during short (<30 minute) procedures. Recent trends in anesthesia-related drug development have touted the benefits of so-called "soft drugs" - these agents, such as remifentanil, are designed to be metabolically fragile and thus susceptible to rapid biotran...
- Indication
Remimazolam is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less.
- Associated Conditions
- Procedural Sedation
- Associated Therapies
- -
Remimazolam for Sedation in ICU Patients Undergoing Mechanical Ventilation
- First Posted Date
- 2021-03-24
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- Tianjin Nankai Hospital
- Target Recruit Count
- 488
- Registration Number
- NCT04815265
Intranasal Remimazolam for Premedication in Pediatric Patient
- Conditions
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2023-09-08
- Target Recruit Count
- 90
- Registration Number
- NCT04720963
- Locations
- 🇨🇳
The second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
Assessment of the Pharmacodynamic and Pharmacokinetic Interaction of Remimazolam and Remifentanil
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Paion UK Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT04670471
- Locations
- 🇳🇱
University Medical Center Groningen, Groningen, Netherlands
REmimazolam Infusion in the Context of Hypnotic Shortage in the Critical Care Unit During the Pandemic of COVID-19: REHSCU Study
- Conditions
- Interventions
- First Posted Date
- 2020-11-02
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04611425
- Locations
- 🇫🇷
CHU de Nantes, Nantes, France
Remimazolam Tosilate Sedation and Midazolam Sedation in Dental Patients
- Conditions
- Interventions
- First Posted Date
- 2020-10-26
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- Peking University
- Target Recruit Count
- 81
- Registration Number
- NCT04602845
- Locations
- 🇨🇳
Peking University Hospital of Stomatology, Beijing, Beijing, China
🇨🇳Zijian Guo, Haidian, Beijing, China
Impact of Remimazolam on Prognosis After Bladder Cancer Surgery
- Conditions
- Interventions
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 1128
- Registration Number
- NCT04532606
- Locations
- 🇨🇳
The Sixth Medical Center of PLA General Hospital, Beijing, Beijing, China
🇨🇳Beijing Tsinghua Chang Gung Hospital, Beijing, Beijing, China
🇨🇳Peking University First Hospital, Beijin, Bejing, China
Oral Remimazolam With and Without Alcohol in Healthy Female Subjects
- First Posted Date
- 2019-10-02
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- Paion UK Ltd.
- Target Recruit Count
- 21
- Registration Number
- NCT04113343
- Locations
- 🇺🇸
PRA Health Sciences (PRA) - Early Development Services, Salt Lake City, Utah, United States
Absolute Oral Bioavailability of Remimazolam
- First Posted Date
- 2019-10-02
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- Paion UK Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT04113564
- Locations
- 🇺🇸
PRA Health Sciences (PRA) - Early Development Services (EDS), Salt Lake City, Utah, United States
Abuse Potential of Intravenous Remimazolam Compared to Midazolam and Placebo in Recreational CNS Depressant Users
- First Posted Date
- 2019-10-01
- Last Posted Date
- 2019-10-01
- Lead Sponsor
- Paion UK Ltd.
- Target Recruit Count
- 83
- Registration Number
- NCT04110535
- Locations
- 🇺🇸
PRA Health Sciences Early Development Services, Salt Lake City, Utah, United States
Comparative Clinical Study of Efficacy and Safety of Remimazolam and Propofol in Patients Undergoing Elective Surgery Under General Anaesthesia
- Conditions
- Interventions
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 150
- Registration Number
- NCT03669484
- Locations
- 🇷🇺
SBHI City Clinical Hospital №1 n.a. N.I. Pirogov, Moscow, Russian Federation
🇷🇺FSBI Central Clinical Hospital and Polyclinic of Adminisatration of the President of the Russian Federation, Moscow, Russian Federation
🇷🇺SBHI Moscow Clinical Research and Practical center of Department of Healthcare of the city of Moscow, Moscow, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.